Cancer 2010-08-15
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy.
ABSTRACT
BACKGROUND
The prognosis of patients with myelodysplastic syndrome (MDS) after decitabine failure is not known.
METHODS
Data from 87 patients with MDS (n=67) and chronic myelomonocytic leukemia (n=.20) after failure of decitabine regimens were reviewed.
RESULTS
After a median follow-up of 21 months from decitabine failure, 13 (15%) patients remained alive; the median survival was 4.3 months, and the estimated 12-month survival rate was 28%. The estimated 12-month survival rates were 27%, 33%, and 33%, respectively, for patients with high-risk, intermediate-2-risk, and intermediate-1-risk disease (P=.99) by the International Prognostic Scoring System. The estimated 12-month survival rates were 100%, 54%, 41%, and 18%, respectively, for patients with low-risk, intermediate-1-risk, intermediate-2-risk, and high-risk disease according to The University of Texas M. D. Anderson Cancer Center risk model (P=.01).
CONCLUSIONS
The outcome of patients after decitabine failure is poor and appears to be predictable after decitabine failure.
Related Questions
Do we continue the hypomethylating agent indefinitely?
New answer by Medical Oncologist at Albert Einstein College of Medicine (June 22, 2018)
The hypomethylating agents (HMA’s, 5-azacitidine & decitabine) have important disease modifying properties in addition to relieving cytopenias for patien...
New answer by Medical Oncologist at Albert Einstein College of Medicine (July 27, 2018)
My choice of first-line therapy for high-risk MDS patients that are not transplant candidates tends to still be a hypomethylating agent (HMA). I send a myeloid molecular profi...